Abstract 26
Background 27
Adipogenesis, the process whereby preadipocytes differentiate into mature adipo-28 cytes, is crucial for maintaining metabolic homeostasis. Cholesterol lowering statins 29 increase type 2 diabetes (T2D) risk possibly by affecting adipogenesis and insulin 30 resistance but the (epi)genetic mechanisms involved are unknown. Here, we charac-31 terised the effects of statin treatment on adipocyte differentiation using in vitro human 32 preadipocytes cell model to identify putative effective genes. 33
Results 34
Statin treatment during adipocyte differentiation caused a reduction in key genes in-35 volved in adipogenesis, such as ADIPOQ, GLUT4 and ABCG1. Using Illumina's Infin-36 ium '850K' Methylation EPIC array, we found a significant hypomethylation of 37 cg14566882, located in the promoter of the histone deacetylase 9 (HDAC9) gene, in 38 response to two types of statins (atorvastatin and mevastatin), which correlates with 39 an increased HDAC9 mRNA expression. HDAC9 is a transcriptional repressor of the 40 cholesterol efflux ABCG1 gene expression, which is epigenetically modified in obesity 41 and prediabetic states. Thus, we assessed the putative impact of ABCG1 knockdown 42 in mimicking the effect of statin in adipogenesis. ABCG1 KD reduced the expression 43
of key genes involved in adipocyte differentiation and decreased insulin signalling 44 and glucose uptake. In human blood cells from two cohorts, ABCG1 expression was 45 impaired in response to statins, confirming that ABCG1 is in vivo targeted by these 46 drugs. 47
Conclusions 48
We identified an epigenetic link between adipogenesis and adipose tissue insulin re-49 sistance in the context of T2D risk associated with statin use, which has important 50 in human preadipocytes and investigated the whole methylome to identify potential 75 regulators that may be involved in adipogenesis. 76 2 Results 77 2.1 Statin treatment reduced adipogenesis and insulin signalling 78
The Simpson-Golabi-Behmel syndrome (SGBS) human preadipocyte cell line was 79 used in this study as an in vitro model for adipocyte differentiation. In SGBS cells, 80 lipid droplet formation occurred by 12-14 days of differentiation together with an in-81 crease in the expression of key adipogenic markers (19) . We retrieved adequate 82 SGBS cell morphology modification and formation of lipids droplets by day 12 (Addi-83 tional File 1: Figure S1a ), and observed that the expression of key genes involved in 84 adipocyte differentiation and maturation was accordingly up-regulated (Additional File 85 1: Figure S1b ). 86
For statin treatment, SGBS cells were differentiated for 6 days and then treated with 87 atorvastatin and mevastatin for an additional 6 days until final maturation (Figure 1a) . 88
We observed a clear decrease in lipid-droplet formation in statin-treated SGBS cells 89 (both atorvastatin and mevastatin) when compared to DMSO-vehicle controls ( Figure  90 1b). We also found that statin-treatment induced a significant down-regulation of 91 many key genes associated with adipogenesis reported above (ABCG1, LEPTIN and 92 GLUT4), with the particular exclusion of PPARG, a gene known to play a role only in 93 the early stages of adipocytes differentiation (Figure 1c ). We then measured the ef-94 fects of statin on downstream regulators of insulin signalling and found decreased 95 efficiency of insulin to activate ERK and AKT ( Figure. 1d ). Taken together, the data 96 support the inhibitory effects of statin in the human adipocyte differentiation and insu-97 lin signalling, a similar effect reported in statin-treated 3T3-L1 mouse adipocyte cells 98 (17). 99 100
Whole methylome analysis of statin-treated SGBS cell line 101
To identify potential regulators involved in statin-induced adipocyte dysregulation, we 102 performed an unbiased whole methylation analysis in statin-treated SGBS cells using 103
Illumina's Infinium '850K' Methylation EPIC arrays (Additional File 1: Figure S2 ). We 104 filtered differentially methylated positions (DMPs) located in the promoter region, an-105 notated as TSS200 or TSS1500 (within 200-1500 base pairs from the transcription 106 start site), in order to identify DMPs that were likely to have a biological effect. The 107 most significant DMP was cg14566882, located in the promoter of the histone deace-108 tylase (HDAC9) gene, in mevastatin-treated cells (β = 8.28 %; p = 5.55 x 10 -6 ) ( Figure  109 2a). This DMP was also significantly hypomethylated in response to atorvastatin 110 treatment, compared to DMSO-vehicle controls (β = 5.53 %; p = 1.35 x 10 -3 ) ( Figure  111 2a, b). 112
Additionally, 87 DMPs were shared between the mevastatin and atorvastatin-treated 113 groups (Additional File 2: Table 1 ) and of the hypomethylated DMPs, cg14566882 in 114 HDAC9 remained the top candidate in both atorvastatin and mevastatin treatments 115 (Additional File 1: Figure S3 ). A significant differentially methylated region (DMR) 116 overlapping this promoter region was also found in response to both treatments (Ad-117 ditional File 1: Figure S4 ; False discovery rate < 0.05). In order to validate the effect 118 of cg14566882 hypomethylation on the expression of the HDAC9 gene, we per-119 formed qPCRs in statin-treated SGBS cell lines and found significant up-regulation of 120 the HDAC9 gene at the mRNA level (p < 0.05; atorvastatin: 14-fold; mevastatin:11-121 fold) ( Figure 2c ). 122 ABCG1 has been reported to be regulated by HDAC9-mediated changes in acetyla-123 tion (20,21) and may be targeted by the HDAC9 epigenetic alteration. We confirmed 124 that ABCG1 protein expression is indeed down-regulated in response to mevastatin 125 and atorvastatin treatment ( Figure 2d ). We confirmed that in response to statin, this 126 effect was independent of the previously reported hypermethylation in cg06500161 127 (p-value > 0.5) and cg27243685 (p-value > 0.5) found to be associated with in-128 creased BMI and T2D incidence (Additional File 1: We performed an ABCG1 knockdown (KD) in SGBS cells to address whether re-132 duced ABCG1 expression mimics the effect of statins in adipogenesis. SGBS preadi-133 pocytes were stably transfected with a shRNA targeting ABCG1 mRNA and followed 134 them quantitatively through maturation and differentiation and this data was com-135 pared with cells transfected with a non-targeting shRNA (control). A similar protocol 136 for stably knockdown Abcg1 via shRNA has previously been achieved and described 137 in mouse 3T3-L1 preadipocytes (25). We initially analysed the expression of ABCG1 138 protein in normal adipocytes to show that it is positively associated with adipogenesis 139 as ABCG1 starts to become expressed at day 6 of differentiation ( Figure 3a ). The 140 efficient silencing of ABCG1 (ABCG1 KD) was confirmed at the protein level ( Figure  141 3b). ABCG1 KD in SGBS cells was accompanied by a significant reduction in the lipid 142 content (20 % reduction, p<0.05; Figure 3c ), along with the down-regulation of the 143 following adipocyte differentiation markers FASN, PPARG and PLIN1 and key adipo-144 cyte maturation markers ADIPOQ and GLUT4 (Figure 3d ). As a consequence of im-145 paired adipogenesis, the ABCG1 KD led to a significant reduction in glucose uptake 146 stimulated by insulin (65 % reduction, p < 0.001; Figure 3e ). In addition, we found a 147 decreased efficiency of insulin to activate AKT in those cells ( Figure 3f ). As a whole, 148 this data indicates that ABCG1 levels are pivotal for the control of human adipocyte 149 differentiation and glucose metabolism. 150 2.4 ABCG1 is down-regulated in response to statin in human blood samples 151
We next explored whether ABCG1 was also dyregulated in samples from human 152 subjects. We analyzed reported transcriptomic data from blood samples from two 153 cohorts. The first consisted of a total of 57 individuals from the ECLIPSE cohort, of 154 which 13 were statin users (26). A significant reduction in the expression of ABCG1 155 in the statin group (p = 1.41 x 10 -5 ) was found, compared to non-users ( Figure 4a ). In 156 addition, we also analysed data from the YELLOW II study (27), a retrospective study 157 following 85 individuals before and following an extensive 8-12 week statin therapy. 158
In peripheral blood mononuclear cells obtained from blood samples, ABCG1 expres-159 sion was significantly decreased following statin treatment, compared to baseline 160 levels, for two ABCG1 probes (ILMN_1794782 p = 2.76 x 10 -5 ; ILMN_2329927 p = 161 4.28 x 10 -4 ) ( Figure 4b ). Taken together, this demonstrates that ABCG1 reduction in 162 response to statin is indeed reflected in human blood samples. Of note, no data on 163 HDAC9 expression was available in the ECLIPSE case control study, and no signifi-164 cant change in HDAC9 expression was reported in the intervention YELLOW II study, 165 maybe due to the lack of sufficient statistical power of this study. 166 167
Discussion 168
A recent 15 year prospective study found a staggering 38 % increased incidence of 169 T2D in statin users, regardless of the type of statin used (28). Here, we report that 170 two statins, atorvastatin and mevastatin, hamper the differentiation process in the 171
SGBS human preadipocyte cell line and decreased insulin sensitivity. 172
We focused our analysis on promoter DMPs, which are normally inversely correlated 173 with expression (29,30). Therefore, not surprisingly, given the inhibitory effect of 174 statin, our whole methylome analysis revealed that most DMPs were hypermethy-175 lated. This includes the IDI1 gene, which encodes the isopentenyl diphosphate isom-176 erase, a component of the cholesterol synthesising pathway (31,32). 177
We report for the first time that statin treatment was associated with a significant hy-178 pomethylation of HDAC9 promoter, which is inversely correlated with HDAC9 gene 179 expression. These findings are of particular significance in light of several studies that 180 demonstrated the key role of HDAC9 in adipocytes function: overexpression of 181
Hdac9 in 3T3-L1 preadipocyte mouse cell lines suppressed adipogenesis and in-182 versely, preadipocytes isolated from Hdac9 knockout mice had an accelerated adipo-183 cyte differentiation (33) . Furthermore, Hdac9 knockout mice showed improved meta-184 bolic homeostasis and were protected from adipose tissue dysfunction in mice fed on 185 a high fat feeding (34). These studies clearly indicate the deleterious role of HDAC9 186 in maintaining adipocytes homeostasis both in vitro and in vivo. 187 HDAC9-deficient macrophages and monocytes directly increased the accumulation 188 of total acetylated H3 and H3K9 at the promoter of the ABCG1 gene (20,21), thereby 189 inducing the transcription of the ABCG1 gene, indicating that HDAC9 mediates the 190 expression of ABCG1 through promoter-mediated acetylation. This is of particular 191 interest, as several studies have reported a role of ABCG1 in obesity, insulin resis-192 tance and T2D. Elevated ABCG1 expression is associated with increased fat mass 193 from obese individuals, suggesting that ABCG1 is also involved in human adipo-194 genesis (25). Although genome-wide association studies have not found any single 195 nucleotide polymorphisms (SNPs) within or nearby ABCG1 associated with increased 196 T2D risk, several EWAS have found that hypermethylation in the ABCG1 gene was 197 associated with fasting glucose, HbA1C levels, lipid metabolism, fasting insulin, T2D 198 risk and BMI (15, 16, 22, (35) (36) (37) (38) . Additional observations in mouse models have shown 199 that Abcg1 -/mice were protected from high fat diet-induced glucose intolerance (39). 200
A recent study found that ABCG1 expression is reduced in both subcutaneous and 201 visceral adipose tissue in morbidly obese patients with metabolic syndrome com-202 pared to those without metabolic syndrome, providing further evidence for a role of 203 ABCG1 in the maintenance of metabolic homeostasis in adipocytes (40). In addition, 204 two studies showed that ABCG1 expression was decreased in blood white human 205 cells in response to statins. As ABCG1 was down-regulated in response to statin, we 206 hypothesised that ABCG1 plays a role in statin-induced adipocyte dysregulation. 207
Indeed, we showed that ABCG1 expression increases during human SGBS adipo-208 cyte differentiation and through ABCG1 silencing, confirm that the level of ABCG1 209 expression is crucial for the appropriate expression of lipid metabolism markers, 210 which include FASN, FABP4, PLIN1 and PPARG, for correct human adipocyte differ-211 entiation. Our findings are consistent with previous data showing variation in these 212 four genes following Abcg1 silencing in mouse 3T3-L1 pre-adipocyte cells (41). The 213 down-regulation of GLUT4 in ABCG1 KD suggested a decrease in insulin-induced 214 glucose uptake. Indeed, we confirmed a down-regulation of phosphorylation of AKT 215 and ERK. Collectively this data indicates that normal ABCG1 function is required for 216 adipogenesis and insulin signalling. In addition, we have confirmed using two sepa-217 rate datasets that statin use was indeed correlated with a reduction in ABCG1 ex-218 pression in human blood samples. Other studies have reported a link between 219 ABCG1 downregulation and diabetes incidence (42) and high fasting glycaemia (43). 220
Taken together, our human cellular data is consistent with human observational stud-221 ies, in which the inhibition of ABCG1 expression was deleterious for metabolism in 222 adipose tissue. 223
Conclusions 224
The model proposed based on our data from statin-induced insulin resistance is hy-225 pomethylation of the HDAC9 promoter induces HDAC9 gene expression, which in 226 turn blocks ABCG1 expression and thereby adipocyte differentiation and metabolic 227 dysfunction ( Figure 5 ). Adipocyte turnover by adipogenesis is crucial for the mainte- least three biological replicates were performed and the data represents the means ± 296
SEM. A two-tailed t-test was performed using GraphPad Prism (GraphPad software 297
Inc., La Jolla, USA) and p-value < 0.05 was considered to be statistically significant. 298
Lipid quantification 299
Culture medium was removed and the cells were washed twice with PBS and then 300 fixed with 10 % formalin for 30 min. Fixed cells were washed twice with water and 301 incubated in 60 % isopropanol for 2 min. The alcohol was discarded and the cells 302 were then incubated in an Oil Red O (Sigma) and water solution (3:2) for 5 min. Cells 303 were rinsed four times with water and then 100 % isopropanol was added to extract 304 the red oil. The absorbance was measured at 540 nm on a VERSAmax ELISA mi-305 croplate reader (Molecular Devices) and analysed using the SoftMax Pro Software 306 (Molecular Devices). 307
Western blotting 308
Cells were washed twice in ice-cold PBS and harvested in RIPA buffer (Ther-309 moFisher Scientific) supplemented with protease inhibitors. Cell lysates were centri-310 fuged at 20,000 x g for 20 min at 4 o C and the total protein lysate was quantified using 311 Bradford Reagent (B6916; Sigma). Then, 40 µg of total protein lysate was separated 312 on a 4-12 % Bis-Tris Plus Gel (Life Technologies) and transferred to a nitrocellulose 313 membrane using the iBlot2 Gel Transfer Device (Life Technologies). Membranes 314 were blocked in 0.5 % non-fat dry milk and probed with anti-ABCG1 (1:1000; 315 ab52617, abcam) and antinuclear matrix protein p84 (1:5,000; ab487, abcam) pri-316 mary antibodies anti-rabbit IgG (1:20,000; Ab205718, abcam) and anti-mouse IgG 317
(1:5,000; A4416, Sigma Aldrich) secondary antibodies for 1 h at room temperature. 318 Membranes were exposed using Clarity Western ECL Substrate (Bio-Rad) and pro-319 tein bands were detected on a LI-COR Imaging system with C-DiGit Image Studio 4.0 320 software (LI-COR Biosciences, Ltd., UK). 
Glucose uptake assay 337
A Glucose Uptake-Glo Assay (J1342; Promega) was used to measure glucose up-338 take in differentiated cells (day 12), according to the manufacturer's protocol. A total 339 of 20,000 cells in 100 µl media were plated in each well of a 96-well white plate. Dif-340 ferentiated cells were cultured overnight in DMEM/F12 media with no serum. On the 341 day of the assay, the media was replaced with 100 µl DMEM/F12 (without glucose or 342 serum) supplemented with or without 1 µM insulin and incubated for 1 h at 37 o C in 343 5 % CO 2 . Cells were washed with PBS and 50 µl 1 mM 2-Deoxy-D-glucose (2DG) 344 was added to each well and incubated for 10 min at room temperature. Next, 25 µl 345
Stop Buffer was added followed by 25 µl Neutralization Buffer per well. Finally, 100 µl 346 2DG6P Detection Reagent was added and incubated for 4.5 h at room temperature. 347
The luminescence was recorded on a Mithras LB 940 luminometer (Berthold Tech-348 nologies) and analysed using the MicroWin Software (Berthold Technologies). 
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